Evidence map›Paper›PMID 42902061›Full record

ArticleInternational journal of clinical oncology2026

Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801.

Keiichiro Ryujin, Kojiro Shirabe, Shota Sato, Akihiko Otake, Yuki Shin, Keita Natsugoe, Tetsuro Kawazoe, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Keiichiro RyujinDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kojiro ShirabeDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shota SatoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Akihiko OtakeDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yuki ShinDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Keita NatsugoeDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tetsuro KawazoeDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Sho NambaraDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasuo TsudaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tomonori NakanokoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Koji AndoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mitsuhiko OtaDepartment of Gastroenterological Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Masaaki IwatsukiDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Hiroshi SaekiDepartment of General Surgical Science, Gastroenterological Surgery, Gunma University, Gunma, Japan.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eiji OkiDepartment of Advanced Medicine and Innovative Technology, Kyushu University, 3-1-1 Maidashi, Higashi-Ku Fukuoka-City, Fukuoka, 812-8582, Japan. oki.eiji.857@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-9763-9366

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of neoadjuvant chemotherapy in elderly patients with locally advanced gastric cancer remains unclear. We evaluated neoadjuvant S-1 plus oxaliplatin (SOX) therapy in elderly patients using patient data from two phase II trials.

methodsPatient data from KSCC1601 and KSCC1801 phase II trials were integrated. Patients were divided into an elderly group (age ≥75 years) and a non-elderly group (age <75 years). Adverse events, postoperative complications, and outcomes were compared. Overall survival (OS) and recurrence-free survival (RFS) were calculated from treatment initiation.

resultsAmong the 73 patients enrolled in trials, 66 (90.4%) underwent surgery and 65 (89.0%) achieved R0 resection. Neoadjuvant SOX therapy was administered to 69 patients (94.5%). Among those with R0 resection, 22 were aged ≥75 years and 43 were aged <75 years. PS 1 was significantly more common in the elderly group, with no other baseline differences. Postoperative complications developed in 11 patients (16.9%), including 1 (4.5%) in the elderly group and 10 (23.3%) in the non-elderly group (p = 0.12). Grade III or higher complications occurred only in the non-elderly group. OS and RFS did not differ significantly between the age groups (OS: Hazard ratio (HR) = 0.78, 95% Confidence Interval (CI) 0.27-2.21, p = 0.64; RFS: HR = 1.12, 95% CI 0.51-2.44, p = 0.79). Undifferentiated histology, stage III disease, and poor pathological response were associated with worse survival.

conclusionsNeoadjuvant SOX therapy is feasible in selected elderly patients with locally advanced gastric cancer and yields survival comparable to those of younger patients.

Indexed as

Elderly patientGastric cancerNeoadjuvant treatmentSOX

Identifiers

PMID42902061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.